Beta-CyclodextrinFormulation
The right cyclodextrin in the right domain
The Peptourbillon® engine classifies every formulation's need for the cyclodextrin and places it in the cake or in the liquid — a decision no off-the-shelf formulation makes.
Panacea research · plaque removal · heart disease
Panacea Bio Chem's beta-cyclodextrin research
Panacea Bio Chem pioneers cyclodextrin formulation inside its own technology stack: a formulation engine that decides where the cyclodextrin belongs, a dual-chamber cartridge that keeps it stable until the moment of use, and low-temperature lyophilisation that preserves it. The target is plaque removal and heart disease.
The research
Peptourbillon®, Panacea's formulation engine, carries a dedicated cyclodextrin classification engine: for every formulation it decides whether hydroxypropyl-beta-cyclodextrin is required, strongly suggested, optional or excluded, and in which domain it belongs — inside the freeze-dried cake or in the liquid of the second chamber.
Lyoprester®, Panacea's dual-chamber cartridge, keeps a freeze-dried cake and its liquid apart until the moment of use; Panacea's low-temperature lyophilisation preserves what the formulation was built to carry.
HW6-Piceid, Panacea's polydatin programme, already pairs the resveratrol glucoside with hydroxypropyl-beta-cyclodextrin as its wetting and delivery partner. HW6-Piceid
Panacea's cyclodextrin research joins these technologies around one goal: cholesterol out of the plaque and out of the body. The compositions, ratios, sequences and process parameters are proprietary and held back by choice.
Three directions
Delivery
Inclusion complexes for the heart
The ring that captures cholesterol also carries guests. Panacea pairs cyclodextrins with cardioprotective molecules, as in its polydatin work[1].
Preservation
Stable until the moment of use
Lyoprester® keeps the freeze-dried cyclodextrin formulation and its liquid apart, sealed, until reconstitution.
The science Panacea builds on
Hydroxypropyl-beta-cyclodextrin dissolves plaque cholesterol crystals and drives regression[2]; it calms the inflammation the crystals cause[3]; and it has a long record of human parenteral use[4,5].
Peptourbillon® is a proprietary Panacea Bio Chem platform developed and invented by Bogdan Dicoias. Its parameters are not publicly disclosed. Lyoprester® is a proprietary Panacea Bio Chem technology developed and invented by Bogdan Dicoias. Its parameters are not publicly disclosed.
Panacea Bio Chem’s cyclodextrin programme
Panacea Bio Chem works on molecules and on everything around them. Compounds are synthesised, tested and experimented with in-house, carried through the company's own analytical gate, and taken into clinical development — the route the NBetaX™ platform is taking with N-BX01, its lead endometriosis candidate. n-bx.com
Panacea Bio Chem owns this thesis: cholesterol already locked inside arterial plaque can be taken out again, with a cyclodextrin built into the right formulation. The lead candidate is the beta-cyclodextrin ring and its hydroxypropyl derivative.
The capability ladder
- Peptourbillon® — the formulation engine, with its dedicated cyclodextrin classification: where the ring belongs, and when it must stay out.
- Lyoprester® — the dual-chamber cartridge that keeps the freeze-dried formulation sealed and stable until use.
- Low-temperature lyophilisation — the cold process that preserves every component of the cake.
- HW6-Piceid — the polydatin–HPβCD inclusion work, the programme’s proof that the ring can carry a cardioprotective partner.
Each rung was invented by Bogdan Dicoias. A cyclodextrin is only as good as the formulation around it. Panacea designs the formulation, prepares it, tests it, keeps it stable in its own container and carries candidates into clinical development — which is why this programme belongs here and not in a catalogue.
The translational pathway
Each stage illuminates as a real milestone is reached; the stages ahead remain outlined.
01
Design
02
Preparation
03
Analytics
04
Formulation
05
Cells
06
Disease models
07
Clinical
08
Plaque resolution
Stage 1
Candidate and ratio discovery
Which ring, at which ratio, with which partner molecule: ranked by cholesterol-binding strength, solubility, tolerability at the intended route and behaviour in the cake.
Stage 2
Formulation and analytics
Prepared in-house, then through the sequential analytical gate — identity, purity, impurity profile, solubility, stability — before anything proceeds to biology.
Stage 3
Cellular and model work
Cholesterol efflux from loaded cells, crystal dissolution, the inflammatory response, and the behaviour of the formulation rather than the bare powder.
Stage 4
Clinical development
The route the company already runs with its lead peptide candidate: clinical-grade manufacture, specifications, dose justification and trial design.
Sequential analytical gate
Only a formulation that passes proceeds
Correct molecular identity · expected molecular mass · chromatographic purity · controlled impurity profile · reproducible preparation · solubility · formulation compatibility · stability under the intended storage and use conditions.
Which cyclodextrin, at what ratio, with which partner molecule, in which chamber and through which process — those are Panacea’s own, held back by choice.
The first goal is a stable cyclodextrin formulation that dissolves the cholesterol in plaque. The next is a medicine. The ultimate goal is the end of atherosclerotic heart disease.
The person behind the resource
Bogdan Dicoias
Biochemist and inventor · Director, Panacea Bio Chem
Panacea Bio Chem's cyclodextrin research is led by Bogdan Dicoias, inventor of the Peptourbillon® formulation engine and the Lyoprester® dual-chamber cartridge. dicoias.com
“Panacea Bio Chem is not merely interested in molecules. Panacea works on the physical, chemical and technological environment surrounding them.”
Bogdan Dicoias
Trending in the field
Recent developments in the field — refreshed 2026-11-07 by Panacea Bio Chem.
- A combination nano-immunotherapy targeting cholesterol crystals and STING signaling enhanced disruption atherosclerotic plaque pathogenesis. — PubMed, 2026
- Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography. — PubMed, 2025
- Cyclodextrin: Dual Functions as a Therapeutic Agent and Nanocarrier for Regulating Cholesterol Homeostasis in Atherosclerosis. — PubMed, 2025
- Reversal of foam cell formation by removal of 7-ketocholesterol with the cyclodextrin dimer UDP-003: a new potential drug candidate to promote atherosclerotic plaque regression. — PubMed, 2025
References
- Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007;329(1-2):1-11. PMID 17137734
- Zimmer S, Grebe A, Bakke SS, Bode N, Halvorsen B, Ulas T, et al.. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med 2016;8(333):333ra50. PMID 27053774
- Bakke SS, Aune MH, Niyonzima N, Pilely K, Ryan L, Skjelland M, et al.. Cyclodextrin Reduces Cholesterol Crystal-Induced Inflammation by Modulating Complement Activation. J Immunol 2017;199(8):2910-2920. PMID 28855312
- Irie T, Fukunaga K, Garwood MK, Carpenter TO, Pitha J, Pitha J. Hydroxypropylcyclodextrins in parenteral use. II: Effects on transport and disposition of lipids in rabbit and humans. J Pharm Sci 1992;81(6):524-8. PMID 1522488
- Carpenter TO, Gerloczy A, Pitha J. Safety of parenteral hydroxypropyl beta-cyclodextrin. J Pharm Sci 1995;84(2):222-5. PMID 7738806
Concept: Bogdan Dicoias · Published by Panacea Bio Chem Scientific Communications · first edition, 7 November 2026 · Evidence last searched 7 November 2026 (PubMed, ClinicalTrials.gov, ANZCTR) — every study cited here was read from its own record.
Panacea Peptides · Panacea Bio Chem · Bogdan Dicoias · Panacea Technologies — the Peptourbillon® formulation engine and the Lyoprester® cartridge are technologies invented by Bogdan Dicoias at Panacea Bio Chem.
